KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. [electronic resource]
Producer: 20150318Description: 33-40 p. digitalISSN:- 1537-453X
- Adenocarcinoma -- drug therapy
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carboplatin -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cisplatin -- administration & dosage
- Disease-Free Survival
- ErbB Receptors -- antagonists & inhibitors
- Female
- Genetic Markers
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation
- Paclitaxel -- administration & dosage
- Prognosis
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins p21(ras)
- Treatment Outcome
- Vinblastine -- administration & dosage
- Vinorelbine
- ras Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.